Repros Therapeutics Inc. Seeks to Affirm Its Intellectual Property Rights in Androxal®
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THE WOODLANDS, Texas, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has filed an action in the United States District Court for the Southern District of Texas seeking a declaratory judgment affirming Repros' intellectual property rights relating to its Androxal® technology. This action is being taken to address issues alleged by a third party relating to the Repros issued patents claiming the use of the pure trans isomer of the drug clomiphene citrate.
Help employers find you! Check out all the jobs and post your resume.
THE WOODLANDS, Texas, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has filed an action in the United States District Court for the Southern District of Texas seeking a declaratory judgment affirming Repros' intellectual property rights relating to its Androxal® technology. This action is being taken to address issues alleged by a third party relating to the Repros issued patents claiming the use of the pure trans isomer of the drug clomiphene citrate.
Help employers find you! Check out all the jobs and post your resume.